Saturn V Capital Management LP holds a focused book of 21 stocks worth $552.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Candel Therapeutics Inc and trimmed Amylyx Pharmaceuticals Inc. Their largest long position is Alumis Inc at 13% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1964437/holdings"
Use Arkolith to show Saturn V Capital Management LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Alumis Inc COM | $70.5M | 3.20M | 12.8% | ▲+2.1% Added · +66K sh | |
| 2 | Amylyx Pharmaceuticals Inc COM | $60.5M | 4.35M | 10.9% | ▼−3.3% Reduced · −147K sh | |
| 3 | Abivax Sa SPONSORED ADS | $60.4M | 542.7K | 10.9% | ▼−16% Reduced · −106K sh | |
| 4 | Vaxcyte Inc COM | $47.9M | 824.5K | 8.7% | ▲+3.2% Added · +26K sh | |
| 5 | Pharvaris N V COM | $33.9M | 1.20M | 6.1% | ▲+5.4% Added · +61K sh | |
| 6 | Immix Biopharma Inc COM | $33.6M | 3.69M | 6.1% | ▲+23% Added · +694K sh | |
| 7 | Celcuity Inc COM | $32.2M | 281.9K | 5.8% | ▼−11% Reduced · −35K sh | |
| 8 | Jazz Pharmaceuticals PLC SHS USD | $30.8M | 163.0K | 5.6% | ▼−34% Reduced · −85K sh | |
| 9 | Disc Medicine Inc COM | $28.8M | 449.9K | 5.2% | ▲+51% Added · +151K sh | |
| 10 | X4 Pharmaceuticals Inc COM NEW | $26.7M | 6.46M | 4.8% | ▲+11% Added · +656K sh | |
| 11 | Cogent Biosciences Inc COM | $24.1M | 626.6K | 4.4% | ▼−49% Reduced · −590K sh | |
| 12 | Monopar Therapeutics Inc COM NEW | $18.9M | 345.6K | 3.4% | ▲+6.1% Added · +20K sh | |
| 13 | Dyne Therapeutics Inc COM | $17.5M | 966.6K | 3.2% | ▼−46% Reduced · −822K sh | |
| 14 | Invivyd Inc COM | $14.2M | 10.95M | 2.6% | ▲+42% Added · +3.2M sh | |
| 15 | Candel Therapeutics Inc COM | $14.2M | 2.90M | 2.6% | ▲New New position | |
| 16 | Oculis Holding AG ORDINARY SHARES | $13.7M | 516.8K | 2.5% | —Held | |
| 17 | Ovid Therapeutics Inc COM | $9.2M | 4.17M | 1.7% | ▲+67% Added · +1.7M sh | |
| 18 | Inhibikase Therapeutics Inc COM NEW | $6.5M | 3.86M | 1.2% | ▲+0.2% Added · +7K sh | |
| 19 | Zura Bio Ltd CLASS A ORD SHS | $4.4M | 740.0K | 0.8% | ▲New New position | |
| 20 | Alto Neuroscience Inc COM SHS | $2.0M | 89.0K | 0.4% | ▲New New position | |
| 21 | Satellos Bioscience Inc COM | $2.0M | 350.0K | 0.4% | ▲New New position |
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.